NCT02873195 - Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

March 6, 2023

Study Completion Date

December 1, 2023

Conditions

Metastatic Colorectal CarcinomaRecurrent Colorectal CarcinomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

Interventions

DRUG

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Capecitabine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given IV

Trial Locations (10)

14263

Roswell Park Cancer Institute, Buffalo

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

55905

Mayo Clinic, Rochester

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

02903

Rhode Island Hospital, Providence

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER